Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia

robot
Abstract generation in progress

Humacyte has announced a significant $1.48 million purchase commitment for its bioengineered vessel, Symvess, from Saudi Health for its deployment in Saudi Arabia. This commitment follows the company’s recent emergency use authorization from the FDA for Symvess to treat vascular trauma. The deal, facilitated by Humacyte’s distributor, the Ministry of Defence Health Services, marks an important step for Symvess in reaching patients in need.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin